**Association between Subclinical Hypothyroidism and Cardiovascular Mortality in Patients Suffered from Heart Failure with Preserved Ejection Fraction**

**Keywords:** Subclinical hypothyroidism; Heart failure with preserved ejection fraction; Cardiovascular mortality; Thyroid stimulating hormone

**Abstract**

**Background:** Subclinical hypothyroidism (SCH) is underdiagnosed in patients with heart disease, however, there has been controversy surrounding whether it is a cardiovascular risk factor or not. To determine the prognostic significance of SCH in Heart Failure (HF) with Preserved Ejection Fraction (HFpEF) we followed a cohort of patients for 9 years.

**Methods:** In this retrospective cohort, we queried our HF data base to identify HFpEF pts diagnosed in 2006 (registry initiation date) based on symptoms, BNP, and echocardiogram with no history of hypothyroidism. Primary outcome was cardiovascular disease (CVD) mortality. Subjects divided into 2 groups based on presence or absence of SCH. SCH was defined as TSH of 5-10 mIU/L and normal free T4 in the absence of symptoms or hypothyroidism history.

**Results:** We identified 249 eligible pts, of who 71 had SCH (28.5%). Mean age was 72.1 ± 13.4 years. Women constituted 56.6%. Follow up was for 8.75 ± 0.17 years. The CVD mortality rate for SCH pts was 29.6% versus 14.9 % for the others (P=0.008). The median survival time for SCH pts was significantly lower than pts with normal thyroid function, 99.9 ± 2.9 and 107.7 ± 1.5 months, respectively (P = 0.008 after adjustment for age, sex, hypertension, and other risk factors) (Figure 1).

**Conclusion:** SCH is a significant predictor of mortality in HFpEF pts, despite controlling for some major risk factors. Therefore a mild asymptomatic elevation in TSH has a significant impact on outcome.

**Background**

Subclinical hypothyroidism (SCH) can be defined as an elevated level of thyroid-stimulating hormone (TSH) with a normal thyroxine (T4) level. The cardiovascular system is one specific target of thyroid hormones. Thyroid hormones, specifically triiodothyronine (T3), are known to have beneficial cardiovascular effects including facilitating myocardial relaxation and lowering peripheral vascular resistance. Derangement of the thyroid axis can thus lead to a spectrum of cardiovascular manifestations. SCH is underdiagnosed in patients with heart disease, however, there has been controversy surrounding whether it is a cardiovascular risk factor or not. This relationship has been studied in heart failure (HF) with reduced ejection fraction (EF), but the frequency of thyroid hormone abnormalities in heart failure with preserved EF (HFpEF) is unknown [1].

Currently, there exists a paucity of evidence on the beneficial effects of thyroxine hormone replacement on cardiovascular mortality outcomes in subclinical hypothyroidism. Also, the clinical relevance of measuring and treating supra-normal TSH levels in newly diagnosed heart failure patients with preserved ejection fraction requires further study. It has been proven beyond doubt that thyroid hormone metabolism can be altered in heart disease. Conversely, thyroid hormone dysfunction can result in altered ventricular contractility/relaxation dynamics and compromised cardiac function. This fact has important clinical implications in that thyroid dysfunction represents one of the few potentially reversible causes of heart failure [2]. Accordingly, we aimed to determine the prognostic significance of SCH in HFpEF through following a cohort of HFpEF patients for 9 years.

**Patients and Methods**

This study was conducted following the approval of advocate health care Institutional Review Board. In this retrospective cohort, our institutional heart failure database was reviewed. All patients HFpEF diagnosis on 2006 were included. All patients with confirmed HFpEF diagnosis based on symptoms, brain natriuretic peptide (BNP), and transthoracic echocardiogram were included. HFpEF patients were identified as patients with symptoms/signs of heart failure with elevated BNP and an ejection fraction of 50% or more.

Primary outcome was cardiovascular disease (CVD) mortality. Subjects divided into 2 groups based on presence or absence of SCH. SCH was defined as TSH of 5-10 mIU/L and normal free T4 in the absence of symptoms or hypothyroidism history.

**Statistical Analysis**

All data including patient’s demographics, medical history, medications, clinical presentation, ECG, and echocardiographic details were obtained from advocate Illinois Masonic clinical records and our prospectively collected databases. In addition, the source for follow-up information was subsequent clinic visits, hospital
membrane iron-channels) leading to higher resistance, stiffness, and effects on the cardiac myocyte (through transcription factors and but mostly related to loss of T3-induced genomic and non-genomic SCH-induced diastolic dysfunction is not completely understood, disease and systolic heart failure, but none were conducted on All the reported studies focused on the presence of coronary artery association of SCH with death from CVD or all-cause mortality. 

Discussion

Based on the above criteria we identified 249 eligible patients, of who 71 had SCH (28.5%). The rest of the patients where those with HFpEF diagnosis as above and normal TSH with no thyroid disease history. Mean age was 72.1 ± 13.4 years. Women constituted 56.6% (141 patients), while men represented 43.4% (108 patients). Mean duration of follow up was for 8.75 ± 0.17 years (Table 1). The CVD mortality rate for SCH patients was 29.6 % versus 14.9 % for the others (P = 0.008), which indicates significant difference and higher mortality risk for patients with SCH. The median survival time for SCH patients was significantly lower than patients with normal thyroid function, 99.9 ± 2.9 and 107.7 ± 1.5 months, respectively. After adjusting for some major risk factors including age, sex, hypertension, diabetes, coronary artery disease, BMI, and atrial fibrillation, SCH remained a significant predictor of mortality in HFpEF (P = 0.008) (based on multivariate regression analysis) (Figure 1).

Results

Based on the above criteria we identified 249 eligible patients, of who 71 had SCH (28.5%). The rest of the patients where those with HFpEF diagnosis as above and normal TSH with no thyroid disease history. Mean age was 72.1 ± 13.4 years. Women constituted 56.6% (141 patients), while men represented 43.4% (108 patients). Mean duration of follow up was for 8.75 ± 0.17 years (Table 1). The CVD mortality rate for SCH patients was 29.6 % versus 14.9 % for the others (P = 0.008), which indicates significant difference and higher mortality risk for patients with SCH. The median survival time for SCH patients was significantly lower than patients with normal thyroid function, 99.9 ± 2.9 and 107.7 ± 1.5 months, respectively. After adjusting for some major risk factors including age, sex, hypertension, diabetes, coronary artery disease, BMI, and atrial fibrillation, SCH remained a significant predictor of mortality in HFpEF (P = 0.008) (based on multivariate regression analysis) (Figure 1).

Li et al. found that subclinical hypo- and hyperthyroidism patients had increased all-cause mortality. However, after adjustment for the baseline variables, only subclinical hyperthyroidism, not subclinical hypothyroidism, was a predictor of all-cause mortality in dilated cardiomyopathy patients. In addition, traditional risk factors for adverse outcomes in HF and dilated cardiomyopathy, such as left ventricular (LV) diameter and LV ejection fraction, although entering the univariate Cox analysis model as the risk factors of all-cause mortality, were not independent prognosis predictors. The difference in the studied populations regarding race and sex ratio as well as the difference in the selected variables included in the Cox multivariate analysis might account for the different outcomes in these studies [7].

In a recent study, the combination of all available large prospective cohorts with 25,378 participants indicates that HF risks higher with any abnormal TSH level regardless if lower or higher, particularly if TSH levels ≥ 10.0 mIU/L or TSH < 0.10 mIU/L. For those with borderline TSH disturbances (TSH levels between 4.50-6.99 mIU/L and TSH levels between 0.10-0.44 mIU/L), no significant difference was in HF risk [8].

Classification systems have been proposed grading subclinical hypothyroidism based on severity assessment into grade 1 (TSH levels < 10 mIU/L) and grade 2 (TSH >10 mIU/L) [9]. The natural history may differ significantly between the two groups with grade 2 category patients having higher cardiovascular events and at higher rates of transition to overt hypothyroidism [10]. A large prospective study involving elderly population (> 85 years) noted an association between grade 1 subclinical hyperthyroidism and decreased all-cause mortality [12]. This was later supported by a large retrospective cohort study which also noted lower mortality rates in grade I impaired diastolic filling.

The heart is particularly vulnerable to the reduction in local triiodothyronine (T3) levels given the essential rule that T3 plays in maintaining cardiac morphology and function. Moreover, thyroid hormone affects cardiac performance through both genomic and non-genomic effects. The genomic nuclear effects play a very significant role in the physiological impact of the thyroid hormone. The main mechanism is through the binding of T3 to specific nuclear thyroid hormone receptors (TRs), which are encoded by the α and β c-erbA proto-oncogene families. TRs act by binding as homodimers or heterodimers to thyroid hormone response elements in the promoter region of some genes [2-5].

Rodondi et al. conducted a literature search regarding the association between subclinical hypothyroidism and coronary heart disease and each of the researchers were invited to join the thyroid study collaboration. After collecting all the information from all the 55, 287 individuals from different cohort studies they concluded that subclinical hypothyroidism is associated with an increased risk of coronary heart disease in those with higher TSH levels. Also, the risk of both CHD mortality and events, increases with higher concentrations of TSH and is significantly elevated in adults with TSH levels of 10 mIU/L or greater. On the other hand, minimal TSH elevations are not associated with an increased risk of CHD events or mortality [6]. This differs from our study in that TSH cutoff in our cohort was 5-10 mIU/L and nevertheless SCH continued to be a significant mortality predictor.
subclinical hypothyroidism patients, suggesting a protective benefit of mildly supra normal TSH levels [11,12]. The same study observed an increase in myocardial infarction events in patients with grade 2 subclinical hypothyroidism. Similarly, an international prospective cohort study of 55287 patients reported increased CHD events and CHD related mortality in these subset of patients [11]. Individual participant data analysis did not identify statistically differing CHD outcomes across the age groups [11]. A new study by Ball M et al. suggested that even coronary collateral circulation can be poor in patients with high TSH and low T3 [13]. Some recent studies suggested the potential benefit of screening patients with diastolic dysfunction especially in the young age group [14].

Given all the conflicting data, it’s in our opinion patients with mildly or significantly elevated TSHand signs/symptoms of heart failure should be aggressively treated despite the existing scarce evidence.

Conclusion

Mild SCH is a significant predictor of mortality in HFpEF patients, despite controlling for all major risk factors. Therefore a mild asymptomatic elevation in TSH has a significant impact on outcome, perhaps as a consequence on left ventricular stiffness.

Limitations

The study was based on only one enters experience. Socioeconomic status was not included and the correlation between metabolic factors was not assessed.

References

9. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, et al. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291: 228-238.

Table 1: Baseline characteristics of patients with HFpEF.

<table>
<thead>
<tr>
<th>Descriptive Statistics</th>
<th>N</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>249</td>
<td>27</td>
<td>98</td>
<td>72.15</td>
<td>13.400</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>249</td>
<td>14.5</td>
<td>93.4</td>
<td>32.16</td>
<td>10.8590</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>249</td>
<td>2.0</td>
<td>191.0</td>
<td>164.358</td>
<td>15.1083</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>249</td>
<td>42.3</td>
<td>852.0</td>
<td>91.335</td>
<td>57.4622</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>249</td>
<td>1.40</td>
<td>197.00</td>
<td>3.9776</td>
<td>17.24746</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>249</td>
<td>1.5</td>
<td>16.4</td>
<td>10.972</td>
<td>2.0200</td>
</tr>
<tr>
<td>Hct (%)</td>
<td>249</td>
<td>20.0</td>
<td>54.5</td>
<td>33.730</td>
<td>5.9931</td>
</tr>
<tr>
<td>Platelets (10³microliter)</td>
<td>249</td>
<td>31.0</td>
<td>600.0</td>
<td>226.789</td>
<td>79.3638</td>
</tr>
<tr>
<td>WBC (10⁹liter)</td>
<td>249</td>
<td>3.3</td>
<td>20.1</td>
<td>8.730</td>
<td>3.0440</td>
</tr>
<tr>
<td>BNP (ng/L)</td>
<td>223</td>
<td>1.1</td>
<td>5000.0</td>
<td>587.270</td>
<td>726.9906</td>
</tr>
<tr>
<td>Cr (mg/dl)</td>
<td>249</td>
<td>0.00</td>
<td>24.90</td>
<td>1.8155</td>
<td>1.82047</td>
</tr>
<tr>
<td>LVESe (mm)</td>
<td>237</td>
<td>1</td>
<td>26</td>
<td>3.16</td>
<td>1.690</td>
</tr>
<tr>
<td>LVEDd (mm)</td>
<td>237</td>
<td>2</td>
<td>8</td>
<td>4.56</td>
<td>0.830</td>
</tr>
<tr>
<td>LVWd (cm)</td>
<td>226</td>
<td>0</td>
<td>3</td>
<td>1.17</td>
<td>0.300</td>
</tr>
<tr>
<td>IVSd(cm)</td>
<td>224</td>
<td>1</td>
<td>4</td>
<td>1.25</td>
<td>0.360</td>
</tr>
<tr>
<td>PAPressure (mmHg)</td>
<td>189</td>
<td>0</td>
<td>89</td>
<td>36.16</td>
<td>17.759</td>
</tr>
<tr>
<td>LAsize (cm)</td>
<td>236</td>
<td>1.0</td>
<td>5.9</td>
<td>3.877</td>
<td>0.8402</td>
</tr>
<tr>
<td>Aortic rootdiameter (cm)</td>
<td>226</td>
<td>0.0</td>
<td>4.5</td>
<td>3.193</td>
<td>0.5189</td>
</tr>
</tbody>
</table>

LVESe: Left Ventricular End Systolic Diameter; LVEDd: Left Ventricular End Diastolic Diameter; LVWd: Left Ventricular Free Wall Thickness; IVSd: Inter Ventricular Septal Thickness.

